Startseite>>Modified Nucleotides>>m6A-ATP,100mM Sodium Solution

m6A-ATP,100mM Sodium Solution

Katalog-Nr.GB20006

m6A-ATP is a base-modified analog of ATP and an adenosine agonist with an ED50 value of 17.250 µM.

Products are for research use only. Not for human use. We do not sell to patients.

m6A-ATP,100mM Sodium Solution Chemische Struktur

Größe Preis Lagerbestand Menge
500μL
990,00 $
Auf Lager
100μL
330,00 $
Auf Lager
1mL
1.600,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product Documents

Quality Control & SDS

View current batch:

Background

m6A-ATP is an adenosine agonist with an ED50 value of 17.250 µM, and is a modulator of adenylate cyclase[1]. m6A-ATP inhibits hemoglobin accumulation and terminal maturation initiation in a concentration-dependent manner. In MEL cells, m6A-ATP reduces the mRNA of β-globin accumulated in the cytoplasm, affecting the structural integrity of this mRNA[2]. m6A-ATP slows down the growth rate of MEL cells, but basically does not inhibit cellular DNA synthesis and reduce cell viability and clonal potential[2]. Adenine, L-homocysteine, and/or L-methionine are all involved in the activated methylation cycle, enhancing m6A-ATP induced inhibition of initiation[3].

M6A modification is the most prevalent, abundant and conserved internal co-transcriptional modification in eukaryotic RNA, especially in higher eukaryotic cells[4]. M6A modification is considered as one of the post-transcriptional regulatory marks of different types of RNAs, including messenger RNAs (mRNAs), transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), circular RNAs (circRNAs), microRNAs (miRNAs) and long Noncoding RNAs (IncRNAs)[4]. M6A modification preferentially occurs within the consensus sequence RRACH (R = G or A; H = A, C or U) in the 3' UTRs and gene coding regions, and is involved in the processing and stability regulation of mRNA[5].

References:
[1]. Ribeiro JA and Sebastio AM. On the type of receptor involved in the inhibitory action of adenosine at the neuromuscular junction. Br J Pharmacol, 1985, 84(4):911-8.
[2]. Sinn P L and Sigmund CD. Human renin mRNA stability is increased in response to cAMP in Calu-6 cells. Hypertension, 1999, 33(3): 900-905.
[3]. Vizirianakis IS, Wong W and Tsiftsoglou AS. Analysis of the inhibition of commitment of murine erythroleukemia (MEL) cells to terminal maturation by N 6-methyladenosine. Biochemical pharmacology, 1992, 44(5): 927-936.
[4]. Shanshan Wang, et al. Dynamic regulation and functions of mRNA m6A modification. Cancer Cell International volume 22, Article number: 48 (2022)..
[5]. Zhao X, Yang Y, Sun BF, et al. FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. Cell research, 2014, 24(12): 1403-1419.

Product Details

purity >99.00% Extinction Coefficient
Formula C11H18N5O13P3(freeacid) M.Wt 521.20(freeacid)
Salt Form Konzentration
Buffer Storage Store at -20°C
Überlieferungen Backbone
Base Analog Sugar Type
Nucleotide Category

Bewertungen

Review for m6A-ATP,100mM Sodium Solution

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for m6A-ATP,100mM Sodium Solution

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.